January 9, 2025 11:06 AM EST

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Kyle LaHucik

Senior Reporter

Biopharma leaders will descend on San Francisco next week hopeful that the industry’s biggest dealmaking event will finally yield some much sought-after M&A.

The industry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Versant unveils Light Horse with $62M and a partnership with Novartis

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Bay­er says elin­zane­tant quelled hot flash­es in women un­der­go­ing can­cer treat­ment

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Versant unveils Light Horse with $62M and a partnership with Novartis

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Aiolos team reunites with $411M for new biotech with obesity drugs from China